Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)

NCT01626378 is registered in ClinicalTrials.gov with TauRx Therapeutics Ltd as lead sponsor.

NCT NCT01626378
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01626378 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Lead sponsor
TauRx Therapeutics Ltd
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2013
Completion date
February 29, 2016
Enrollment
220 (actual)
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

behavioral variant frontotemporal dementia (bvftd)